Resveratrol Güçlü Bir Antioksidan Mı?

Yıl 2021, Cilt: 2 Sayı: 1, 57 - 63, 30.06.2021

Emine Sarman Kanat Gülle

Öz

Serbest radikaller, oksidatif hasara neden olan ve kronik dejeneratif hastalıklara yol açan toksik maddelerdir. Serbest radikal oluşumunu önleyen veya bu radikallerin temizlenmesini sağlayan maddelere “antioksidan” adı verilmektedir. Bir antioksidan olan resveratrol üzüm ve ürünleri başta olmak üzere 70’den fazla bitki çeşidinde bulunan bir fitoaleksindir. Resveratrolün oksidatif stresi azalttığı, kan-beyin bariyerini geçtiği, birçok hastalık üzerine iyileştirici rolünün olduğu görülmüştür. Fakat insan sağlığı üzerinde kesin bir koruyucu etkisinin olduğunu söyleyebilmek için daha ileri çalışmalara ihtiyaç olduğu düşünülmektedir.

Anahtar Kelimeler

Serbest Radikal, Oksidatif Stres, Resveratrol, Antioksidan

Destekleyen Kurum

Yok.

Proje Numarası

Yok.

Teşekkür

Yok.

Kaynakça

• 1. Sroka, Z., & Cisowski, W. (2003). Hydrogen peroxide scavenging, antioxidant and anti-radical activity of some phenolic acids. Food and Chemical Toxicology, 41(6), 753–758. https://doi.org/10.1016/S0278-6915(02)00329-0
• 2. Prior, R. L., & Cao, G. (2000). Antioxidant phytochemicals in fruits and vegetables: Diet and health implications. HortScience, 35(4), 588–592. https://doi.org/10.21273/HORTSCI.35.4.588
• 3. Bonnefont-Rousselot, D., Beaudeux, J.-L., Thérond, P., Peynet, J., Legrand, A., & Delattre, J. (2004). Diabetes mellitus, oxidative stress and advanced glycation endproducts. Annales Pharmaceutiques Fancaises, 62(3), 147–157. https://doi.org/10.1016/s0003-4509(04)94297-6
• 4. Moe, G. W., Marin-Garcia, J., Konig, A., Goldenthal, M., Lu, X., & Feng, Q. (2004). In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. American Journal of Physiology-Heart and Circulatory Physiology, 287(4), H1813-20. https://doi.org/10.1152/ajpheart.00036.2004
• 5. Aydemir, B., & Sarı, E. K. (2009). Antioksidanlar ve büyüme faktörleri ile ilişkisi. Kocatepe Veteriner Dergisi, 2(2), 56–60.
• 6. Larson, R. A. (1988). The antioxidants of higher plants. Phytochemistry, 27(4), 969–978. https://doi.org/10.1016/0031-9422(88)80254-1
• 7. Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., Shishodia, S., & Takada, Y. (2004). Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Research, 24(5A), 2783–2840.
• 8. Walle, T. (2011). Bioavailability of resveratrol. Annals of the New York Academy of Sciences, 1215, 9–15. https://doi.org/10.1111/j.1749-6632.2010.05842.x
• 9. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E. J., & Walle, U. K. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition, 32(12), 1377–1382. https://doi.org/10.1124/dmd.104.000885
• 10. Cai, H., Scott, E., Kholghi, A., Andreadi, C., Rufini, A., Karmokar, A., … Brown, K. (2015). Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. Science Translational Medicine, 7(298), 298ra117. https://doi.org/10.1126/scitranslmed.aaa7619
• 11. Chung-man Ho, J., Zheng, S., Comhair, S. A., Farver, C., & Erzurum, S. C. (2001). Differential expression of manganese superoxide dismutase and catalase in lung cancer. Cancer Research, 61(23), 8578–8585.
• 12. Gromadzinska, J., Wasowicz, W., Rydzynski, K., & Szeszenia-Dabrowska, N. (2003). Oxidative-stress markers in blood of lung cancer patients occupationally exposed to carcinogens. Biological Trace Element Research, 91(3), 203–215. https://doi.org/10.1385/BTER:91:3:203
• 13. Lee, J., Koo, N., & Min, D. B. (2004). Reactive oxygen species, aging, and antioxidative nutraceuticals. Comprehensive Reviews in Food Science and Food Safety, 3(1), 21–33. https://doi.org/10.1111/j.1541-4337.2004.tb00058.x
• 14. Turna, G., Kılıç, N., Yıldırım, Z., & Sarı, S. (2011). Ehrlich asit solid tümör modeli oluşturulmuş farelerde Thymus sipyleus ve Taurinin Karaciğer MDA, GSH, AOPP düzeylerine ve SOD aktivitesine etkileri. Türkiye Klinikleri Tıp Bilimleri Dergisi, 31(5), 1153–1159.
• 15. Balcı, N. (2007). Sürekli gürültüye maruz kalınan bazı iş kollarında çalışan kişilerde serum total sialik asit ksantin oksidaz malondialdehit nitrik oksit arginaz ve ornitin değerleri. (Yayımlanmamış yüksek lisans tezi). Kahramanmaraş Sütçü İmam Üniversitesi Fen Bilimleri Enstitüsü, Kimya Anabilim Dalı, Kahramanmaraş.
• 16. Günaydın, B., & Çelebi, H. (2003). Genel anesteziklerin serbest radikaller ve antioksidanlarla ilişkisi. Anestezi Dergisi, 11(2), 87–98.
• 17. German, J. B. (1999). Food processing and lipid oxidation. Advances in Experimental Medicine and Biology, 459, 23–50. https://doi.org/10.1007/978-1-4615-4853-9_3
• 18. Besler, H. T., & Comoğlu, S. (2003). Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutritional Neuroscience, 6(3), 189–196. https://doi.org/10.1080/1028415031000115945
• 19. Scandalios, J. G. (2002). The rise of ROS. Trends in Biochemical Sciences, 27(9), 483–486. https://doi.org/10.1016/s0968-0004(02)02170-9
• 20. Şengül, C. A. (2010). Obez olgularda İnsülin direnci, metabolik sendrom ile total oksidan ve antioksidan düzeyleri ilişkisi. (Tıpta uzmanlık tezi). Gaziantep Üniversitesi, Tıp Fakültesi İç Hastalıkları Ana Bilim Dalı, Gaziantep.
• 21. Guidetti, M., Sforzini, A., Bersani, G., Corsini, C., Grossi, G., Zolezzi, C., … Pironi, L. (2008). Vitamin A and vitamin E isoforms stability and peroxidation potential of all-in-one admixtures for parenteral nutrition. International Journal for Vitamin and Nutrition Research, 78(3), 156–166. https://doi.org/10.1024/0300-9831.78.3.156
• 22. Angın, Y. (2009). Pediatrik obezite ile ilişkili yağlı karaciğer hastalığında metabolik, oksidan ve antioksidan sistemik belirteçlerin değerlendirilmesi. (Yayımlanmamış yüksek lisans tezi). Dokuz Eylül Üniversitesi Sağlık Bilimleri Enstitüsü Biyokimya Ana Bilim Dalı, İzmir.
• 23. Özata, M., Yılmaz, M. İ., Mergen, M., Öktenli, Ç., & Aydın, A. (2003). Erkek obezitesinde bozulmuş antioksidan kapasite ve hipoçinkonemi. Turkish Journal of Endocrinology and Metabolism, Suppl. 2, 47–51.
• 24. Khan, N. I., Naz, L., & Yasmeen, G. (2006). Obesity: An independent risk factor for systemic oxidative stress. Pakistan Journal of Pharmaceutical Sciences, 19(1), 62–65.
• 25. Valenzano, D. R., & Cellerino, A. (2006). Resveratrol and the pharmacology of aging: A new vertebrate model to validate an old molecule. Cell Cycle, 5(10), 1027–1032. https://doi.org/10.4161/cc.5.10.2739
• 26. Chung, S., Yao, H., Caito, S., Hwang, J.-W., Arunachalam, G., & Rahman, I. (2010). Regulation of SIRT1 in cellular functions: Role of polyphenols. Archives of Biochemistry and Biophysics, 501(1), 79–90. https://doi.org/10.1016/j.abb.2010.05.003
• 27. Sarkar, F. H., Li, Y., Wang, Z., & Kong, D. (2009). Cellular signaling perturbation by natural products. Cellular Signalling, 21(11), 1541–1547. https://doi.org/10.1016/j.cellsig.2009.03.009
• 28. Vanamala, J., Reddivari, L., Radhakrishnan, S., & Tarver, C. (2010). Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer, 10, 238. https://doi.org/10.1186/1471-2407-10-238
• 29. Alayev, A., Salamon, R. S., Schwartz, N. S., Berman, A. Y., Wiener, S. L., & Holz, M. K. (2017). Combination of rapamycin and resveratrol for treatment of bladder cancer. Journal of Cellular Physiology, 232(2), 436–446. https://doi.org/10.1002/jcp.25443
• 30. Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W., Hoffmann, E., Hegarty, B., … Gescher, A. J. (2011). Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prevention Research, 4(9), 1419–1425. https://doi.org/10.1158/1940-6207.CAPR-11-0148
• 31. Tomé-Carneiro, J., Larrosa, M., González-Sarrías, A., Tomás-Barberán, F. A., García-Conesa, M. T., & Espín, J. C. (2013). Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Current Pharmaceutical Design, 19(34), 6064–6093. https://doi.org/10.2174/13816128113199990407
• 32. Kulkarni, S. S., & Cantó, C. (2015). The molecular targets of resveratrol. Biochimica et Biophysica Acta, 1852(6), 1114–1123. https://doi.org/10.1016/j.bbadis.2014.10.005
• 33. Paller, C. J., Rudek, M. A., Zhou, X. C., Wagner, W. D., Hudson, T. S., Anders, N., … Carducci, M. A. (2015). A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. The Prostate, 75(14), 1518–1525. https://doi.org/10.1002/pros.23024
• 34. Kjaer, T. N., Ornstrup, M. J., Poulsen, M. M., Jørgensen, J. O. L., Hougaard, D. M., Cohen, A. S., … Pedersen, S. B. (2015). Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men. The Prostate, 75(12), 1255–1263. https://doi.org/10.1002/pros.23006
• 35. Schneider, Y., Vincent, F., Duranton, B., Badolo, L., Gossé, F., Bergmann, C., … Raul, F. (2000). Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lettersers, 158(1), 85–91. https://doi.org/10.1016/s0304-3835(00)00511-5
• 36. Patel, K. R., Brown, V. A., Jones, D. J. L., Britton, R. G., Hemingway, D., Miller, A. S., … Brown, K. (2010). Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Research, 70(19), 7392–7399. https://doi.org/10.1158/0008-5472.CAN-10-2027
• 37. Jazirehi, A. R., & Bonavida, B. (2004). Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin’s lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Molecular Cancer Therapeutics, 3(1), 71–84.
• 38. Sale, S., Tunstall, R. G., Ruparelia, K. C., Potter, G. A., Steward, W. P., & Gescher, A. J. (2005). Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4’-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. International Journal of Cancer, 115(2), 194–201. https://doi.org/10.1002/ijc.20884
• 39. Zhu, W., Qin, W., Zhang, K., Rottinghaus, G. E., Chen, Y.-C., Kliethermes, B., & Sauter, E. R. (2012). Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutrition and Cancer, 64(3), 393–400. https://doi.org/10.1080/01635581.2012.654926
• 40. Pasinetti, G. M., Wang, J., Ho, L., Zhao, W., & Dubner, L. (2015). Roles of resveratrol and other grape-derived polyphenols in Alzheimer’s disease prevention and treatment. Biochimica et Biophysica Acta, 1852(6), 1202–1208. https://doi.org/10.1016/j.bbadis.2014.10.006
• 41. Huang, Y., & Mucke, L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell, 148(6), 1204–1222. https://doi.org/10.1016/j.cell.2012.02.040
• 42. Moussa, C., Hebron, M., Huang, X., Ahn, J., Rissman, R. A., Aisen, P. S., & Turner, R. S. (2017). Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. Journal of Neuroinflammation, 14(1), 1. https://doi.org/10.1186/s12974-016-0779-0
• 43. Turner, R. S., Thomas, R. G., Craft, S., van Dyck, C. H., Mintzer, J., Reynolds, B. A., … Aisen, P. S. (2015). A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology, 85(16), 1383–1391. https://doi.org/10.1212/WNL.0000000000002035
• 44. Thordardottir, S., Kinhult Ståhlbom, A., Almkvist, O., Thonberg, H., Eriksdotter, M., Zetterberg, H., … Graff, C. (2017). The effects of different familial Alzheimer’s disease mutations on APP processing in vivo. Alzheimer’s Research & Therapy, 9(1), 9. https://doi.org/10.1186/s13195-017-0234-1
• 45. World Health Organisation. (2017). Cardiovascular diseases (CVDs). Retrieved from World Health Organisation website: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
• 46. Magyar, K., Halmosi, R., Palfi, A., Feher, G., Czopf, L., Fulop, A., … Szabados, E. (2012). Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clinical Hemorheology and Microcirculation, 50(3), 179–187. https://doi.org/10.3233/CH-2011-1424
• 47. Agarwal, B., Campen, M. J., Channell, M. M., Wherry, S. J., Varamini, B., Davis, J. G., … Smoliga, J. M. (2013). Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene expression in vascular endothelium. International Journal of Cardiology, 166(1), 246–248. https://doi.org/10.1016/j.ijcard.2012.09.027
• 48. Tomé-Carneiro, J., Gonzálvez, M., Larrosa, M., García-Almagro, F. J., Avilés-Plaza, F., Parra, S., … Espín, J. C. (2012). Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Molecular Nutrition & Food Research, 56(5), 810–821. https://doi.org/10.1002/mnfr.201100673
• 49. Biesinger, S., Michaels, H. A., Quadros, A. S., Qian, Y., Rabovsky, A. B., Badger, R. S., & Jalili, T. (2016). A combination of isolated phytochemicals and botanical extracts lowers diastolic blood pressure in a randomized controlled trial of hypertensive subjects. European Journal of Clinical Nutrition, 70(1), 10–16. https://doi.org/10.1038/ejcn.2015.88
• 50. Bo, S., Ciccone, G., Castiglione, A., Gambino, R., De Michieli, F., Villois, P., … Cassader, M. (2013). Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Current Medicinal Chemistry, 20(10), 1323–1331. https://doi.org/10.2174/0929867311320100009
• 51. Zortea, K., Franco, V. C., Francesconi, L. P., Cereser, K. M. M., Lobato, M. I. R., & Belmonte-de-Abreu, P. S. (2016). Resveratrol supplementation in schizophrenia patients: A randomized clinical trial evaluating serum glucose and cardiovascular risk factors. Nutrients, 8(2), 73. https://doi.org/10.3390/nu8020073
• 52. van der Made, S. M., Plat, J., & Mensink, R. P. (2015). Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: A randomized, placebo-controlled crossover trial. PloS One, 10(3), e0118393. https://doi.org/10.1371/journal.pone.0118393